Neuroprotection Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
- 99S4131237
- 87 Pages
- December 2020
- Healthcare
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Neuroprotection market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Neuroprotection market segmented into
Free Radical Trapping Agents (Antioxidants)
Glutamate Antagonists (Anti-Excitotoxic Agents)
Apoptosis Inhibitors
Anti-inflammatory Agents
Neurotrophic Factors (NTFs)
Metal Ion Chelators
Stimulants
Others
Based on the end-use, the global Neuroprotection market classified into
Prevention
Treatment
Based on geography, the global Neuroprotection market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
Daiichi Sankyo Company
Eli Lilly and Company
Allergan
Dr. Reddy’s Laboratories
Teva Pharmaceutical
Novartis
AstraZeneca
Astrocyte Pharmaceuticals
F. Hoffmann-La Roche
Biogen
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL NEUROPROTECTION INDUSTRY
2.1 Summary about Neuroprotection Industry
2.2 Neuroprotection Market Trends
2.2.1 Neuroprotection Production & Consumption Trends
2.2.2 Neuroprotection Demand Structure Trends
2.3 Neuroprotection Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Free Radical Trapping Agents (Antioxidants)
4.2.2 Glutamate Antagonists (Anti-Excitotoxic Agents)
4.2.3 Apoptosis Inhibitors
4.2.4 Anti-inflammatory Agents
4.2.5 Neurotrophic Factors (NTFs)
4.2.6 Metal Ion Chelators
4.2.7 Stimulants
4.2.8 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Prevention
4.3.2 Treatment
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Free Radical Trapping Agents (Antioxidants)
5.2.2 Glutamate Antagonists (Anti-Excitotoxic Agents)
5.2.3 Apoptosis Inhibitors
5.2.4 Anti-inflammatory Agents
5.2.5 Neurotrophic Factors (NTFs)
5.2.6 Metal Ion Chelators
5.2.7 Stimulants
5.2.8 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Prevention
5.3.2 Treatment
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Free Radical Trapping Agents (Antioxidants)
6.2.2 Glutamate Antagonists (Anti-Excitotoxic Agents)
6.2.3 Apoptosis Inhibitors
6.2.4 Anti-inflammatory Agents
6.2.5 Neurotrophic Factors (NTFs)
6.2.6 Metal Ion Chelators
6.2.7 Stimulants
6.2.8 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Prevention
6.3.2 Treatment
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Free Radical Trapping Agents (Antioxidants)
7.2.2 Glutamate Antagonists (Anti-Excitotoxic Agents)
7.2.3 Apoptosis Inhibitors
7.2.4 Anti-inflammatory Agents
7.2.5 Neurotrophic Factors (NTFs)
7.2.6 Metal Ion Chelators
7.2.7 Stimulants
7.2.8 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Prevention
7.3.2 Treatment
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Free Radical Trapping Agents (Antioxidants)
8.2.2 Glutamate Antagonists (Anti-Excitotoxic Agents)
8.2.3 Apoptosis Inhibitors
8.2.4 Anti-inflammatory Agents
8.2.5 Neurotrophic Factors (NTFs)
8.2.6 Metal Ion Chelators
8.2.7 Stimulants
8.2.8 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Prevention
8.3.2 Treatment
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Free Radical Trapping Agents (Antioxidants)
9.2.2 Glutamate Antagonists (Anti-Excitotoxic Agents)
9.2.3 Apoptosis Inhibitors
9.2.4 Anti-inflammatory Agents
9.2.5 Neurotrophic Factors (NTFs)
9.2.6 Metal Ion Chelators
9.2.7 Stimulants
9.2.8 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Prevention
9.3.2 Treatment
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Daiichi Sankyo Company
10.1.2 Eli Lilly and Company
10.1.3 Allergan
10.1.4 Dr. Reddy’s Laboratories
10.1.5 Teva Pharmaceutical
10.1.6 Novartis
10.1.7 AstraZeneca
10.1.8 Astrocyte Pharmaceuticals
10.1.9 F. Hoffmann-La Roche
10.1.10 Biogen
10.2 Neuroprotection Sales Date of Major Players (2017-2020e)
10.2.1 Daiichi Sankyo Company
10.2.2 Eli Lilly and Company
10.2.3 Allergan
10.2.4 Dr. Reddy’s Laboratories
10.2.5 Teva Pharmaceutical
10.2.6 Novartis
10.2.7 AstraZeneca
10.2.8 Astrocyte Pharmaceuticals
10.2.9 F. Hoffmann-La Roche
10.2.10 Biogen
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
Table Neuroprotection Product Type Overview
Table Neuroprotection Product Type Market Share List
Table Neuroprotection Product Type of Major Players
Table Brief Introduction of Daiichi Sankyo Company
Table Brief Introduction of Eli Lilly and Company
Table Brief Introduction of Allergan
Table Brief Introduction of Dr. Reddy’s Laboratories
Table Brief Introduction of Teva Pharmaceutical
Table Brief Introduction of Novartis
Table Brief Introduction of AstraZeneca
Table Brief Introduction of Astrocyte Pharmaceuticals
Table Brief Introduction of F. Hoffmann-La Roche
Table Brief Introduction of Biogen
Table Products & Services of Daiichi Sankyo Company
Table Products & Services of Eli Lilly and Company
Table Products & Services of Allergan
Table Products & Services of Dr. Reddy’s Laboratories
Table Products & Services of Teva Pharmaceutical
Table Products & Services of Novartis
Table Products & Services of AstraZeneca
Table Products & Services of Astrocyte Pharmaceuticals
Table Products & Services of F. Hoffmann-La Roche
Table Products & Services of Biogen
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Neuroprotection Market Forecast (Million USD) by Region 2021f-2026f
Table Global Neuroprotection Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Neuroprotection Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Neuroprotection Market Forecast (Million USD) Share by Demand 2021f-2026f
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
